US › Healthcare

Castle Biosciences Inc (CSTL)

US · Healthcare · Diagnostics & Research

$31.18+2.60%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$103.5M
Revenue YoY
+20.1%
Net profit
$-2.1M
Profit YoY
-145.5%
EPS
$-0.07
EPS estimate
$-0.44
Net margin
-2.0%

EPS came in at -0.07 against a street estimate of -0.44 — a beat of 84.1%.

Key statistics

Market cap
$855.4M
Forward P/E
0.0
P/B
1.82
Book value
$15.41
EPS (TTM)
$-0.64
52-week high
$44.28
52-week low
$17.72
50-day MA
$22.67
200-day MA
$28.86
Beta
1.00

Analyst view

Analysts rate Castle Biosciences Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $43.56.

Shareholding

Insiders
2.71%
Institutions
91.90%

Largest institutional holders

FundStake
BlackRock Inc9.76%
RTW INVESTMENTS, LLC9.03%
Principal Financial Group Inc5.79%
Portolan Capital Management, LLC4.42%
Vanguard Capital Management, LLC3.85%
Dimensional Fund Advisors, Inc.3.40%
Summit Partners Public Asset Management, LLC3.08%
Vanguard Portfolio Management, LLC2.82%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Castle Biosciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.